Macular‐type cutaneous adverse reaction due to atezolizumab and pembrolizumab

Anti‐PD‐1/PD‐L1 targeted therapy is widely used for the treatment of various intractable malignancies and develops the therapeutic option in the frontier fields of oncology treatment. On the contrary, these immune checkpoint therapies sometimes develop undesirable adverse reaction as the results of activation of immune reaction to various organs. Herein, we report a case of cutaneous adverse reactions during PD‐1/PD‐L1 targeted treatment in both atezolizumab and pembrolizumab in a patient with lung cancer.